Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Promoter hypermethylation of the RASSF1A gene predicts the poor outcome of patients with hepatoblastoma.

Pediatric blood & cancer - 1 Sept 2007

Sugawara Waka, Haruta Masayuki, Sasaki Fumiaki, Watanabe Naoki, Tsunematsu Yukiko, Kikuta Atsushi, Kaneko Yasuhiko

Abstract excerpt

BACKGROUND: Despite the progress of therapy, about 25% of patients with hepatoblastoma succumb to the disease. Prognostic factors, as well as improved therapies, are needed for these patients. We investigated the incidence and clinical significance of genetic and epigenetic aberrations in hepatoblastoma. PROCEDURE: beta-catenin mutation was analyzed by sequencing and promoter hypermethylation of the RASSF1A and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta Catenin
Share to Eye Proteins

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gene Silencing

Share to Hepatoblastoma

Share to Intercellular Signaling Peptides and Proteins

Share to Multivariate Analysis

Share to Survival Rate

Share to Tumor Suppressor Proteins

Source

Identifiers

PMID: 16937357
DOI: 10.1002/pbc.21031

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Promoter hypermethylation of the RASSF1A gene predicts the poor outcome of patients with hepatoblastoma.PMID 16937357Read ↗

The methylation status of RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in hepatoblastoma patients.Semantic proximity Read ↗

RASSF1A methylation indicates a poor prognosis in hepatoblastoma patients.Semantic proximity Read ↗

Role of RASSF1A promoter methylation in the pathogenesis of hepatocellular carcinoma: a meta-analysis of 21 cohort studies.Semantic proximity Read ↗

RASSF1A and SOCS1 genes methylation status as a noninvasive marker for hepatocellular carcinomaSemantic proximity Read ↗

Clinical prognostic value of DNA methylation in hepatoblastoma: Four novel tumor suppressor candidatesSemantic proximity Read ↗

DNA methylation markers and serum α-fetoprotein level are prognostic factors in hepatocellular carcinomaSemantic proximity Read ↗

Aberrant promoter methylation of RASSF1A gene may be correlated with colorectal carcinogenesis: a meta-analysis.Semantic proximity Read ↗

DNA methylation as a key epigenetic player for hepatoblastoma characterizationSemantic proximity Read ↗

RASSF1A hypermethylation is associated with aflatoxin B1 and polycyclic aromatic hydrocarbon exposure in hepatocellular carcinoma.Semantic proximity Read ↗

RASSF1A and DOK1 Promoter Methylation Levels in Hepatocellular Carcinoma, Cirrhotic and Non-Cirrhotic Liver, and Correlation with Liver Cancer in Brazilian PatientsSemantic proximity Read ↗

The tumor suppressor RASSF1A in human carcinogenesis: an update.Semantic proximity Read ↗

Downregulation of SFRP1 is a protumorigenic event in hepatoblastoma and correlates with beta-catenin mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.